Literature DB >> 9747681

Intraocular concentrations of chemotherapeutic agents after systemic or local administration.

M E Mendelsohn1, D H Abramson, T Madden, W Tong, H T Tran, I J Dunkel.   

Abstract

OBJECTIVES: To investigate the concentrations of carboplatin and etoposide achieved in the aqueous and vitreous humors after intravenous infusion in nonhuman primates, and to investigate whether local administration of carboplatin might result in higher concentrations in the vitreous humor.
METHODS: Macaca fascicularis primates were treated with 1 of 3 regimens: (1) intravenous carboplatin (18.7 mg/kg), etoposide (5 mg/kg), and vincristine sulfate (0.05 mg/kg), (2) peribulbar carboplatin (10 mg/mL), or (3) episcleral balloon carboplatin (10 mg/mL). Concentrations of chemotherapeutic agents were measured in the plasma and in the aqueous and vitreous humors.
RESULTS: No measurable amount of etoposide was detected in the aqueous or vitreous humor after intravenous administration. Mean measured peak vitreous concentration of carboplatin after intravenous administration was 0.31 microg/mL, which was 1% of the peak plasma value. Mean measured peak vitreous concentrations of carboplatin after peribulbar or episcleral balloon administration were 2.38 microg/mL and 2.95 microg/mL, respectively, which represent 7.68- and 9.52-fold increases over the concentration achieved after intravenous administration. No serious toxic effect was observed in any animal.
CONCLUSIONS: Peribulbar and episcleral balloon administration of carboplatin seemed to be safe and resulted in higher vitreous concentrations than intravenous administration in this model. These results suggest that these alternate routes of delivery should be explored in children with vitreous seeding of retinoblastoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747681     DOI: 10.1001/archopht.116.9.1209

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy.

Authors:  C L Shields; E M Fulco; J D Arias; C Alarcon; M Pellegrini; P Rishi; S Kaliki; C G Bianciotto; J A Shields
Journal:  Eye (Lond)       Date:  2012-09-21       Impact factor: 3.775

3.  A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231).

Authors:  Rima F Jubran; Judith G Villablanca; Mark Krailo; Jin Piao; Li Huang; A Linn Murphree; Joan O'Brien; Dan Gombos; Carol L Shields; Anna Meadows; Murali Chintagumpala
Journal:  Pediatr Blood Cancer       Date:  2020-06-26       Impact factor: 3.167

Review 4.  Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.

Authors:  Eleanor M Pritchard; Michael A Dyer; R Kiplin Guy
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 5.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Localization of multidrug resistance-associated protein 2 in the nonpigmented ciliary epithelium of the eye.

Authors:  Ryan M Pelis; Mohammad Shahidullah; Sikha Ghosh; Miguel Coca-Prados; Stephen H Wright; Nicholas A Delamere
Journal:  J Pharmacol Exp Ther       Date:  2009-02-06       Impact factor: 4.030

7.  Safety and efficacy of posterior sub-Tenon's carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds.

Authors:  Azza Mohamed Ahmed Said; Mohamed Gamil Aly; Hazem Omar Rashed; Anwaar Mahmoud Rady
Journal:  Int J Ophthalmol       Date:  2018-03-18       Impact factor: 1.779

8.  Treatment of retinoblastoma: current status and future perspectives.

Authors:  Carlos Rodriguez-Galindo; Guillermo L Chantada; Barrett G Haik; Matthew W Wilson
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

Review 9.  Risk definition and management strategies in retinoblastoma: current perspectives.

Authors:  Fariba Ghassemi; Alireza Khodabande
Journal:  Clin Ophthalmol       Date:  2015-06-08

10.  Sonic hedgehog: its expression in a healing cornea and its role in neovascularization.

Authors:  Kyoko Fujita; Takeshi Miyamoto; Shizuya Saika
Journal:  Mol Vis       Date:  2009-05-18       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.